RxDoctor Payments Data

Kerry Gomulka, PA

Physician Assistant · Goshen, NYNPI 1639126162

Payments from drug & device makers

$11,866in general payments, 2019–2025

Across 652 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$801
  • GSK$636
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$11,77299%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,866 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$24,710
Medicare patients
140
Services billed
398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$45,421
FarxigaDapagliflozin Propanediol35$33,065
EliquisApixaban17$29,013
MounjaroTirzepatide19$21,827
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$17,502
TradjentaLinagliptin11$16,525
XareltoRivaroxaban23$15,778
Repatha SyringeEvolocumab18$13,877
UbrelvyUbrogepant12$11,756
EntrestoSacubitril/Valsartan14$10,922
Albuterol Sulfate HfaAlbuterol Sulfate80$3,896
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$3,495
SynthroidLevothyroxine Sodium38$2,800
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$2,570
Lisdexamfetamine Dimesylate12$2,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,004$45,42141 claims
AstraZenecaFarxiga$1,446$33,06535 claims
PfizerEliquis$801$29,01317 claims
Lilly USA, LLCMounjaro$1,481$21,82719 claims
GSKTrelegy Ellipta$636$17,50212 claims
Boehringer IngelheimTradjenta$632$16,52511 claims
Johnson & JohnsonXarelto$203$15,77823 claims
AbbVieUbrelvy, Synthroid$2,142$14,55650 claims
NovartisEntresto$236$10,92214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Goshen

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →